# Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer

> **NCT00044993** · PHASE2 · COMPLETED · sponsor: **Introgen Therapeutics**

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** Ad5CMV-p53 gene
- **DRUG:** docetaxel
- **DRUG:** doxorubicin hydrochloride
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** neoadjuvant therapy

## Key facts

- **NCT ID:** NCT00044993
- **Lead sponsor:** Introgen Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** —
- **Final completion:** 2004-08
- **Target enrollment:** — (—)
- **Last updated:** 2013-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044993, "Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00044993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*